On September 10, EVEREST MED fell 5.38% in regular trading, trading at 29.32 HKD/share, with turnover of 31.71 million HKD, extending the pullback for a second consecutive session.

On the news front, the company announced on September 3 that Xingbituo (etripamil nasal spray) received NMPA approval for the treatment of acute episodes of paroxysmal supraventricular tachycardia (PSVT) in adults, marking the first and only innovative therapy approved for this indication in over 30 years. The approval initially drove a rally of over 5% on September 8, but the stock has since entered a typical post-catalyst profit-taking phase, having already retraced the prior gains with a 5% decline on September 9. Meanwhile, the company disclosed a strategic cooperation framework agreement with Haisen Biopharmaceutical on September 9, setting a cumulative procurement cap of 3.076 billion RMB for the period through the end of 2028. The broader Biotechnology sector remained under pressure, with INNOVENT BIO down 2.29%, 3SBIO down 2.41%, and SKB BIO down 1.62%, adding further drag on the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)